布地奈德、异丙托溴铵、α糜蛋白酶联合雾化吸入治疗AECOPD疗效观察  

The Clinical Observation of AECOPD Treated with Budesonide, Ipratropium Bromide Combined with Chymotrypsin Atomization Inhalation

作　　者：孙红[1] 

机构地区：[1]江苏省苏州市吴中区长桥人民医院,江苏苏州215128

出　　处：《中国医学创新》2014年第34期76-78,共3页Medical Innovation of China

摘　　要：目的:研究联合布地奈德、异丙托溴铵、α糜蛋白酶氧气雾化吸入治疗急性加重的慢性阻塞性肺疾病(AECOPD)的疗效。方法:40例AECOPD患者随机数字表法分为治疗组和对照组两组,每组20例。对照组常规给予抗感染、止咳化痰、解痉平喘、吸氧等治疗,治疗组在常规治疗基础上联合布地奈德、异丙托溴铵、α糜蛋白酶氧气雾化吸入治疗,2次/d,共7 d,对比观察两组患者临床疗效,喘憋消失时间、肺部哮鸣音消失时间、肺部X线改善时间、住院时间及治疗前后C反应蛋白(CRP)、白细胞计数(WBC)和脉搏血氧饱和度(Sp O2)水平和不良反应。结果:治疗组总有效率90%,对照组总有效率65%,两组比较有差异有统计学意义(P<0.05);治疗组患者在喘憋消失时间、肺部哮鸣音消失时间、肺部X线改善时间、住院时间等方面,均短于对照组,两组比较差异有统计学意义(P<0.05);两组患者治疗后CRP、WBC水平较治疗前均降低,而Sp O2水平升高,各组患者治疗前后的差异均有统计学意义(P<0.05),且治疗后CRP、WBC、Sp O2水平比较,治疗组较对照组改变更为明显。结论:联合布地奈德、异丙托溴铵、α糜蛋白酶氧气雾化吸入治疗AECOPD临床疗效好、安全可靠、副作用少。Objective： To research the clinical effect of budesonide, Ipratropium bromide combined with Chymotrypsin Atomization inhalation treatment on AECOPD patients. Method： 40 patients with AECOPD were randomly divided into treatment group and control group, 20 cases in each group. Patients in the control group were given conventional treatment, on the basis of conventional treatment, patients in treatment group were given budesonide, isopropyl bromide, alpha chymotrypsin oxygen atomization inhalation therapy, 2 times a day, treated for 7 days. The clinical curative effect, lung wheezing sound disappear time, lung X-ray improvement time, length of hospital stay and c-reactive protein（CRP）, white blood cell count（WBC） and pulse oxygen saturation（SpO2） levels before and after the treatment and adverse reactions between the two groups were compared. Result： The total effective rate of the treatment group was 90%, while the total effective rate of the control group was 65%, there was significant difference between the two groups（P〈0.05）. The disappeared time of asthma, lung wheezing sound disappear time, lung X-ray improvement time, length of hospital stay in treatment group were significantly shorter than those of the control group（P〈0.05）. The levels of CRP, WBC after treatment between both groups were lower than before treatment, while the level of SpO2 was higher, the difference was statistically significant（P0.05）. The changes of CRP, WBC, SpO2 in the treatment group were more obvious than those of the control group（P〈0.05）. Conclusion： The clinical effect of budesonide, Ipratropium bromide combined with Chymotrypsin Atomization inhalation treatment on AECOPD patients is effective, safe and reliable, and it has less side effects.

关 键 词：AECOPD 布地奈德 异丙托溴铵 Α糜蛋白酶 

分 类 号：R563.9[医药卫生—呼吸系统]